0 Comments
23 October 2008
NEWS: Boosting access to medicines
National Party Leader John Key says a National-led Government will provide New Zealanders with broader access to medicines, including new funding for Herceptin.
To view National's medicines policy visit:
http://national.org.nz/files/2008/HEALTH/medicines_policy.pdf
"National recognises that many Kiwis have limited access to modern medicines. We will improve that access. We will boost overall funding for medicines and speed up the registration of new medicines, with final approval remaining in New Zealand."
"National will boost funding for medicines over three years to expand the availability of subsidised medicines. Funding will increase over present levels by $40 million in year one, $60 million in year two, and $80 million in year three. We will increase this funding further if economic conditions allow.
"These initiatives will be funded within the indicative health spending allocations in the PREFU. They are also further examples of our determination to shift spending into frontline services for patients, rather than backroom costs.
"New Zealanders are increasingly uneasy about the limited range of publicly funded medicines available here compared to what is available in other countries.
"Countries we like to compare ourselves with – such as Australia – spend more, in part because they have higher incomes. Australia provides much better access to medicines than New Zealand does.
"It is clear that in the medium term only better economic performance overall will enable us to spend significantly more on healthcare. National is firmly focused on achieving that growth.
In the short-term New Zealand must strive to get more services from existing health spending by reducing waste and bureaucracy, and by lifting productivity."
National will also:
• Work with stakeholders to investigate ways to improve access to high-cost highly specialised medicines.
• Establish a process of unilateral recognition of the registration and approval of medicines. We will retain Medsafe's capacity to fully evaluate new medicine applications as appropriate.
• Fund 12-month access to Herceptin for early Her-2 positive breast cancer sufferers, recognising the overwhelming international evidence and consensus of cancer specialists.
About 12% of New Zealand's public health spending goes on medicines compared to an average of 18% in the OECD. Public funding per person on pharmaceuticals in New Zealand is only two-thirds of what it is in Australia.
"This boost in medicines funding will mean real per-person funding for medicines will gradually increase under a National-led Government. It will broaden access to medicines for many New Zealanders."
To view National's medicines policy visit:
http://national.org.nz/files/2008/HEALTH/medicines_policy.pdf Tweet
To view National's medicines policy visit:
http://national.org.nz/files/2008/HEALTH/medicines_policy.pdf
"National recognises that many Kiwis have limited access to modern medicines. We will improve that access. We will boost overall funding for medicines and speed up the registration of new medicines, with final approval remaining in New Zealand."
"National will boost funding for medicines over three years to expand the availability of subsidised medicines. Funding will increase over present levels by $40 million in year one, $60 million in year two, and $80 million in year three. We will increase this funding further if economic conditions allow.
"These initiatives will be funded within the indicative health spending allocations in the PREFU. They are also further examples of our determination to shift spending into frontline services for patients, rather than backroom costs.
"New Zealanders are increasingly uneasy about the limited range of publicly funded medicines available here compared to what is available in other countries.
"Countries we like to compare ourselves with – such as Australia – spend more, in part because they have higher incomes. Australia provides much better access to medicines than New Zealand does.
"It is clear that in the medium term only better economic performance overall will enable us to spend significantly more on healthcare. National is firmly focused on achieving that growth.
In the short-term New Zealand must strive to get more services from existing health spending by reducing waste and bureaucracy, and by lifting productivity."
National will also:
• Work with stakeholders to investigate ways to improve access to high-cost highly specialised medicines.
• Establish a process of unilateral recognition of the registration and approval of medicines. We will retain Medsafe's capacity to fully evaluate new medicine applications as appropriate.
• Fund 12-month access to Herceptin for early Her-2 positive breast cancer sufferers, recognising the overwhelming international evidence and consensus of cancer specialists.
About 12% of New Zealand's public health spending goes on medicines compared to an average of 18% in the OECD. Public funding per person on pharmaceuticals in New Zealand is only two-thirds of what it is in Australia.
"This boost in medicines funding will mean real per-person funding for medicines will gradually increase under a National-led Government. It will broaden access to medicines for many New Zealanders."
To view National's medicines policy visit:
http://national.org.nz/files/2008/HEALTH/medicines_policy.pdf Tweet
